Sima Porten, MD, MPH

Associate Professor
Urology
+1 415 353-7171

Dr. Sima Porten is a specialist in cancers of the genital and urinary organs. She is a member of the urologic oncology team at the UCSF Helen Diller Family Comprehensive Cancer Center. Her clinical interests include the diagnosis and treatment of genitourinary cancer, particularly bladder cancer, upper tract urothelial cancer, kidney cancer and high-risk prostate cancer.

Porten's research focuses mainly on the diagnosis and management of urothelial carcinoma, a cancer involving parts of the kidney, bladder and ureter (the tube connecting each kidney to the bladder). In studying the biologic or genetic basis of urothelial carcinoma, she hopes to develop new tests and treatments to bring personalized medicine to patients with bladder cancer.

Porten received her undergraduate, medical and master of public health degrees from Northwestern University. During medical school, she was inducted into the Alpha Omega Alpha Honor Medical Society and also completed a fellowship through the Howard Hughes Medical Institute–National Institutes of Health Research Scholars Program. She then completed her urology residency training at UCSF, where she received the Julius R. Krevans Award for Clinical Excellence. During her training in urologic oncology at the University of Texas MD Anderson Cancer Center, she was awarded a John Quale Travel Fellowship for her research in bladder cancer.

Porten is an active member of the American Urological Association, American Society of Clinical Oncology, Society of Women in Urology and Society of Urologic Oncology.

Publications: 

HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains.

The oncologist

Zhu X, Chan E, Turski ML, Mendez CE, Hsu SC, Kumar V, Shipp C, Jindal T, Chang K, Onodera C, Devine WP, Grenert JP, Stohr BA, Ding CC, Stachler MD, Quigley DA, Feng FY, Chu CE, Porten SP, Chou J, Friedlander TW, Koshkin VS

Urine Biopsy as Dynamic Biomarker to Enhance Clinical Staging of Bladder Cancer in Radical Cystectomy Candidates.

JCO precision oncology

Satyal U, Valentine H, Liu D, Slifker M, Lallas CD, Trabulsi EJ, Bukavina L, Szeto L, Hoffman-Censits JH, Mouw KW, Faltas BM, Grivas P, Ibragimova I, Porten SP, Van Allen EM, Geynisman DM, Parker DC, O'Neill JP, Drevik J, Christianson SS, Ginzburg S, Correa AF, Uzzo RG, Ross EA, Zibelman MR, Ghatalia P, Plimack ER, Kutikov A, Abbosh PH

"I think my vagina is still there?": Women's perspectives on sexual function and dysfunction following radical cystectomy for bladder cancer, a qualitative study.

The journal of sexual medicine

Ceasar RC, Ladi-Seyedian SS, Escobar D, Han J, Koh K, Porten S, Chu C, Gould EE, Bhanvadia S

Predicting Peak Productivity in Urologic Medicare Practice via Work-Relative Value Units.

Urology

Briggs LG, Labban M, Ye J, Herzog P, Jones AN, Nguyen DD, Wallis CJD, Wolter C, Porten S, Trinh QD

Association of household net worth with healthcare costs after radical cystectomy using real-world data.

Cancer medicine

Washington SL, Lonergan PE, Odisho AY, Meng MV, Porten SP

Evaluation of URO17® to improve non-invasive detection of bladder cancer.

Urologic oncology

Porten SP, Wang EY, Vohra P, Carroll PR, Jahanfard S, Kim NW

Racial Differences in the Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry.

Cancers

Ladi-Seyedian SS, Ghoreifi A, Konety B, Pohar K, Holzbeierlein JM, Taylor J, Kates M, Willard B, Taylor JM, Liao JC, Kaimakliotis HZ, Porten SP, Steinberg GD, Tyson MD, Lotan Y, Daneshmand S

Initial Experience with 68Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Koshkin VS, Kumar V, Kline B, Escobar D, Aslam M, Cooperberg MR, Aggarwal RR, de Kouchkovsky I, Chou J, Meng MV, Friedlander T, Porten S, Hope TA

Standardization of the evaluation and surveillance of patients with BCG unresponsive high grade non-muscle invasive bladder cancer clinical trials.

Urologic oncology

Lotan Y, Agarwal P, Black P, Dickstein R, Kamat AM, Lee B, Narayan VM, Porten S, Psutka SP, Smith AK, Svatek RS, Williams SB, Woldu S

Commentary on Novitas LCD.

Bladder cancer (Amsterdam, Netherlands)

Lotan Y, Barocas DA, Chang SS, Daneshmand S, Konety B, Meeks JJ, Porten S, Raman JD, Rosser CJ, Scarpato KR, Sexton WJ, Sfakianos JP, Shore ND, Svatek RS

Wake-Up Call to Address Sleep Health in Non-Muscle Invasive Bladder Cancer: Underappreciated Contributor to Poor Quality of Life.

Bladder cancer (Amsterdam, Netherlands)

Wang EY, Armas-Phan M, Meng MV, Loeb S, Kenfield SA, Porten SP

Interruptions in bladder cancer care during the COVID-19 public health emergency.

Urologic oncology

Gore JL, Follmer K, Reynolds J, Nash M, Anderson CB, Catto JWF, Chamie K, Daneshmand S, Dickstein R, Garg T, Gilbert SM, Guzzo TJ, Kamat AM, Kates MR, Lane BR, Lotan Y, Mansour AM, Master VA, Montgomery JS, Morris DS, Nepple KG, O'Neil BB, Patel S, Pohar K, Porten SP, Riggs SB, Sankin A, Scarpato KR, Shore ND, Steinberg GD, Strope SA, Taylor JM, Comstock BA, Kessler LG, Wolff EM, Smith AB

Protocol of the Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) study: a pragmatic, prospective multicenter observational cohort study of recurrent high-grade non-muscle invasive bladder cancer.

BMC cancer

Gore JL, Wolff EM, Comstock BA, Follmer KM, Nash MG, Basu A, Chisolm S, MacLean DB, Lee JR, Lotan Y, Porten SP, Steinberg GD, Chang SS, Gilbert SM, Kessler LG, Smith AB, CISTO Collaborative

Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer.

Bladder cancer (Amsterdam, Netherlands)

Chang E, Hahn NM, Lerner SP, Fallah J, Agrawal S, Kamat AM, Bhatnagar V, Svatek RS, Jaigirdar AA, Bross P, Shore N, Kates M, Sachse K, Brewer JR, O'Donnell MA, Steinberg GD, Viviano CJ, Bloomquist E, Ribal MJ, Galsky MD, Oliver R, Black PC, Al-Ahmadie H, Brothers K, Pohar K, Dinney CP, Feng Z, Downs TM, Porten SP, Smith AB, Bangs R, Psutka SP, Agarwal N, Amiri-Kordestani L, Suzman DL, Pazdur R, Kluetz PG, Weinstock C

Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605.

European urology

Black PC, Tangen CM, Singh P, McConkey DJ, Lucia MS, Lowrance WT, Koshkin VS, Stratton KL, Bivalacqua TJ, Kassouf W, Porten SP, Bangs R, Plets M, Thompson IM, Lerner SP

Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE).

European urology focus

Kates M, Chu X, Hahn N, Pietzak E, Smith A, Shevrin DH, Crispen P, Williams SB, Daneshmand S, Packiam VT, Porten S, Westerman ME, Wagner LI, Carducci M

Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma PatientsTreated With Immune Checkpoint Inhibitors or Enfortumab Vedotin.

Clinical genitourinary cancer

Jindal T, Zhang L, Deshmukh P, Reyes K, Chan E, Kumar V, Zhu X, Maldonado E, Feng S, Johnson M, Angelidakis A, Kwon D, Desai A, Borno HT, Bose R, Wong A, Hong J, Carroll P, Meng M, Porten S, Aggarwal R, Small EJ, Fong L, Chou J, Friedlander T, de Kouchkovsky I, Koshkin VS

Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer.

Frontiers in oncology

Jindal T, Zhu X, Bose R, Kumar V, Maldonado E, Deshmukh P, Shipp C, Feng S, Johnson MS, Angelidakis A, Kwon D, Borno HT, de Kouchkovsky I, Desai A, Aggarwal R, Fong L, Small EJ, Wong A, Porten S, Chou J, Friedlander T, Koshkin VS

Cxbladder Monitor testing to reduce cystoscopy frequency in patients with bladder cancer.

Urologic oncology

Li KD, Chu CE, Patel M, Meng MV, Morgan TM, Porten SP

Is a restaging TURBT necessary in high-risk NMIBC if the initial TURBT was performed with blue light?

Urologic oncology

Alsyouf M, Ladi-Seyedian SS, Konety B, Pohar K, Holzbeierlein JM, Kates M, Willard B, Taylor JM, Liao JC, Kaimakliotis HZ, Porten SP, Steinberg GD, Tyson MD, Lotan Y, Daneshmand S, Blue Light Cystoscopy with Cysview Registry Group

Epidemiology, Screening, and Prevention of Bladder Cancer.

European urology oncology

Lobo N, Afferi L, Moschini M, Mostafid H, Porten S, Psutka SP, Gupta S, Smith AB, Williams SB, Lotan Y

Sex-specific Augmentation of Treatment Responses in Bladder Cancer.

European urology open science

Chang K, Porten SP

Origins and Timing of Emerging Lesions in Advanced Renal Cell Carcinoma.

Molecular cancer research : MCR

Wallace A, Porten SP, Lo AA, Oreper D, Lounsbury N, Havnar C, Pechuan-Jorge X, Zill OA, Meng MV

Survey Results on Use of a Convex Pouching System in the Postoperative Period.

Journal of wound, ostomy, and continence nursing : official publication of The Wound, Ostomy and Continence Nurses Society

Stoia-Davis J, Colwell JC, Emodi K, Fellows J, Mahoney M, McDade B, Porten SP, Raskin ER, Norman HS, Kelly MT, Sims T

Use of a Convex Pouching System in the Postoperative Period: A National Consensus.

Journal of wound, ostomy, and continence nursing : official publication of The Wound, Ostomy and Continence Nurses Society

Colwell JC, Stoia Davis J, Emodi K, Fellows J, Mahoney M, McDade B, Porten S, Raskin E, Sims T, Norman H, Kelly MT, Gray M

Holistic Characterization of Tumor Monocyte-to-Macrophage Differentiation Integrates Distinct Immune Phenotypes in Kidney Cancer.

Cancer immunology research

Mujal AM, Combes AJ, Rao AA, Binnewies M, Samad B, Tsui J, Boissonnas A, Pollack JL, Argüello RJ, Meng MV, Porten SP, Ruhland MK, Barry KC, Chan V, Krummel MF

Systematic review of sleep and sleep disorders among prostate cancer patients and caregivers: a call to action for using validated sleep assessments during prostate cancer care.

Sleep medicine

Robbins R, Cole D O R, Ejikeme C, Orstad SL, Porten S, Salter CA, Sanchez Nolasco T, Vieira D, Loeb S

APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer.

Frontiers in oncology

Natesan D, Zhang L, Martell HJ, Jindal T, Devine P, Stohr B, Espinosa-Mendez C, Grenert J, Van Ziffle J, Joseph N, Umetsu S, Onodera C, Turski M, Chan E, Desai A, Aggarwal R, Wong A, Porten S, Chou J, Friedlander T, Fong L, Small EJ, Sweet-Cordero A, Koshkin VS

TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.

European urology oncology

Chou J, Trepka K, Sjöström M, Egusa EA, Chu CE, Zhu J, Chan E, Gibb EA, Badura ML, Contreras-Sanz A, Stohr BA, Meng MV, Pruthi RS, Lotan Y, Black PC, Porten SP, Koshkin VS, Friedlander TW, Feng FY

Role of blue-light cystoscopy in detecting invasive bladder tumours: data from a multi-institutional registry.

BJU international

Ahmadi H, Ladi-Seyedian SS, Konety B, Pohar K, Holzbeierlein JM, Kates M, Willard B, Taylor JM, Liao JC, Kaimakliotis HZ, Porten SP, Steinberg GD, Tyson MD, Lotan Y, Daneshmand S, Blue Light Cystoscopy with Cysview Registry Group

Utility of Blue Light Cystoscopy for Post-bacillus Calmette-Guérin Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study Comparisons.

The Journal of urology

Chappidi MR, Yang H, Meng MV, Bivalacqua TJ, Daneshmand S, Holzbeierlein JM, Kaimakliotis HZ, Konety B, Liao JC, Pohar K, Steinberg GD, Taylor JM, Tyson MD, Willard B, Lotan Y, Porten SP, Kates M

Urothelial Carcinoma and Prostate-specific Membrane Antigen: Cellular, Imaging, and Prognostic Implications.

European urology focus

Tariq A, McCart Reed AE, Morton A, Porten S, Vela I, Williams ED, Yaxley JW, Black PC, Roberts MJ

Applicant perceptions of virtual interviews for society of urologic oncology fellowships during the COVID-19 pandemic.

Urologic oncology

Gore JL, Porten SP, Montgomery JS, Hamilton RJ, Meng MV, Sexton WJ, Psutka SP

Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin.

Clinical cancer research : an official journal of the American Association for Cancer Research

Chu CE, Sjöström M, Egusa EA, Gibb EA, Badura ML, Zhu J, Koshkin VS, Stohr BA, Meng MV, Pruthi RS, Friedlander TW, Lotan Y, Black PC, Porten SP, Feng FY, Chou J

Association of smoking status and recurrence of non-muscle invasive bladder cancer among patients managed with blue light cystoscopy.

Urologic oncology

Matulewicz RS, Ravvaz K, Weissert JA, Porten S, Steinberg GD, Blue Light Cystoscopy with Cysview Registry Group

TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor.

Journal for immunotherapy of cancer

de Kouchkovsky I, Zhang L, Philip EJ, Wright F, Kim DM, Natesan D, Kwon D, Ho H, Ho S, Chan E, Porten SP, Wong AC, Desai A, Huang FW, Chou J, Oh DY, Pruthi RS, Fong L, Small EJ, Friedlander TW, Koshkin VS

Research highlights of the 2020 society of urologic oncology young urologic oncologists' program.

Urologic oncology

Klaassen Z, Scarpato KR, Ristau BT, Stratton KL, Porten SP, Smaldone MC, Chapin BF, Psutka SP

Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer.

European urology

Chu CE, Alshalalfa M, Sjöström M, Zhao SG, Liu Y, Chou J, Herlemann A, Mahal B, Kishan AU, Spratt DE, Cooperberg M, Small E, Wong A, Porten S, Hope TA, Ross AE, Davicioni E, Nguyen P, Karnes RJ, Carroll PR, Schaeffer E, Feng FY

Liposomal Bupivacaine Decreases Postoperative Length of Stay and Opioid Use in Patients Undergoing Radical Cystectomy.

Urology

Chu CE, Law L, Zuniga K, Lin TK, Tsourounis C, Rodriguez-Monguio R, Lazar A, Washington SL, Cooperberg MR, Greene KL, Carroll PR, Pruthi RS, Meng MV, Chen LL, Porten SP

Women in Leadership in Urology: The Case for Increasing Diversity and Equity.

Urology

Chyu J, Peters CE, Nicholson TM, Dai JC, Taylor J, Garg T, Smith AB, Porten SP, Greene K, Browning N, Harris E, Sutherland SE, Psutka SP

Assessing Contemporary Trends in Female Speakership within Urologic Oncology.

Urology

Talwar R, Bernstein A, Jones A, Crook J, Apolo AB, Taylor JM, Burke LM, Plimack ER, Porten SP, Greene KL, Psutka SP, Smith AB

Bladder tumor recurrence after urothelial carcinoma of the upper urinary tract.

Translational andrology and urology

Lonergan PE, Porten SP

Bladder cancer in patients younger than 40 years: outcomes from the National Cancer Database.

World journal of urology

de la Calle CM, Washington SL, Lonergan PE, Meng MV, Porten SP

Using provider-focused education toolkits can aid enhanced recovery programs to further reduce patient exposure to opioids.

Perioperative medicine (London, England)

Sarin A, Lancaster E, Chen LL, Porten S, Chen LM, Lager J, Wick E

Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer.

Cell

Oh DY, Kwek SS, Raju SS, Li T, McCarthy E, Chow E, Aran D, Ilano A, Pai CS, Rancan C, Allaire K, Burra A, Sun Y, Spitzer MH, Mangul S, Porten S, Meng MV, Friedlander TW, Ye CJ, Fong L

Reply by Authors.

The Journal of urology

de Jong JJ, Liu Y, Boorjian SA, Bivalacqua TJ, Porten SP, Wheeler T, Davicioni E, Svatek RS, Boormans JL, Black PC, Lotan Y, Gibb EA

Lifestyle and Non-muscle Invasive Bladder Cancer Recurrence, Progression, and Mortality: Available Research and Future Directions.

Bladder cancer (Amsterdam, Netherlands)

Zuniga KB, Graff RE, Feiger DB, Meng MV, Porten SP, Kenfield SA

Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences.

European urology oncology

de Jong JJ, Boormans JL, van Rhijn BWG, Seiler R, Boorjian SA, Konety B, Bivalacqua TJ, Wheeler T, Svatek RS, Douglas J, Wright J, Dall'Era M, Crabb SJ, Efstathiou JA, van der Heijden MS, Mouw KW, Miyamoto DT, Lotan Y, Black PC, Gibb EA, Porten SP

TCF21 Promotes Luminal-Like Differentiation and Suppresses Metastasis in Bladder Cancer.

Molecular cancer research : MCR

Mokkapati S, Porten SP, Narayan VM, Lim AH, Jayaratna IS, Roth B, Cheng T, Navai N, Wszolek M, Melquist J, Manyam G, Choi W, Broom B, Pretzsch S, Czerniak B, McConkey DJ, Dinney CPN

A Genomic Classifier for Predicting Clinically Aggressive Luminal Bladder Tumors with Higher Rates of Pathological Up Staging.

The Journal of urology

de Jong JJ, Liu Y, Boorjian SA, Bivalacqua TJ, Porten SP, Wheeler T, Davicioni E, Svatek RS, Boormans JL, Black PC, Lotan Y, Gibb EA

Role of Indoleamine-2,3-Dioxygenase Inhibitors in Salvage Therapy for Non-Muscle Invasive Bladder Cancer.

The Urologic clinics of North America

Chu CE, Porten SP, Grossfeld GD, Meng MV

Promotion Disparities in Academic Urology.

Urology

Breyer BN, Butler C, Fang R, Meeks W, Porten SP, North AC, Anger JT

Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials.

Clinical cancer research : an official journal of the American Association for Cancer Research

Kates M, Matoso A, Choi W, Baras AS, Daniels MJ, Lombardo K, Brant A, Mikkilineni N, McConkey DJ, Kamat AM, Svatek RS, Porten SP, Meeks JJ, Lerner SP, Dinney CP, Black PC, McKiernan JM, Anderson C, Drake CG, Bivalacqua TJ

Optimizing cystectomy outcomes.

Cancer

Porten SP, Master VA

Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy.

European urology

Konety B, Shore N, Kader AK, Porten S, Daneshmand S, Lough T, Lotan Y

Social Determinants of Appropriate Treatment for Muscle-Invasive Bladder Cancer.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Washington SL, Neuhaus J, Meng MV, Porten SP

Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors.

European urology

Lotan Y, Boorjian SA, Zhang J, Bivalacqua TJ, Porten SP, Wheeler T, Lerner SP, Hutchinson R, Francis F, Davicioni E, Svatek RS, Chen CL, Black PC, Gibb EA

The Association Between Race and Frailty in Older Adults Presenting to a Nononcologic Urology Practice.

Urology

Washington SL, Porten SP, Quanstrom K, Jin C, Bridge M, Finlayson E, Walter LC, Suskind AM

Determinants of Guideline-Based Treatment in Patients With cT1 Bladder Cancer.

Clinical genitourinary cancer

Balakrishnan AS, Washington SL, Meng MV, Porten SP

Epigenetic Alterations in Bladder Cancer.

Current urology reports

Porten SP

Do Women Work Less Than Men in Urology: Data From the American Urological Association Census.

Urology

Porten SP, Gaither TW, Greene KL, Baradaran N, Anger JT, Breyer BN

Integrative analysis of the epigenetic basis of muscle-invasive urothelial carcinoma.

Clinical epigenetics

Sanford T, Meng MV, Railkar R, Agarwal PK, Porten SP

The Cancer of the Bladder Risk Assessment (COBRA) score: Estimating mortality after radical cystectomy.

Cancer

Welty CJ, Sanford TH, Wright JL, Carroll PR, Cooperberg MR, Meng MV, Porten SP

Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasis.

Oncotarget

Roth B, Jayaratna I, Sundi D, Cheng T, Melquist J, Choi W, Porten S, Nitti G, Navai N, Wszolek M, Guo C, Czerniak B, McConkey D, Dinney C

Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy.

European urology focus

Kukreja JB, Porten S, Golla V, Ho PL, Noguera-Gonzalez G, Navai N, Kamat AM, Dinney CPN, Shah JB

Development and Validation of Consensus Contouring Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy.

International journal of radiation oncology, biology, physics

Baumann BC, Bosch WR, Bahl A, Birtle AJ, Breau RH, Challapalli A, Chang AJ, Choudhury A, Daneshmand S, El-Gayed A, Feldman A, Finkelstein SE, Guzzo TJ, Hilman S, Jani A, Malkowicz SB, Mantz CA, Master V, Mitra AV, Murthy V, Porten SP, Richaud PM, Sargos P, Efstathiou JA, Eapen LJ, Christodouleas JP

The Efficient and Effective Use of Exfoliative Urinary Markers.

Urology practice

Whitson JM, Porten SP, Hussein AA, Meng MV

Intravesical chemotherapy in non-muscle-invasive bladder cancer.

Indian journal of urology : IJU : journal of the Urological Society of India

Porten SP, Leapman MS, Greene KL

Untreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes.

The Journal of urology

Hussein AA, Welty CJ, Ameli N, Cowan JE, Leapman M, Porten SP, Shinohara K, Carroll PR

Updated trends in imaging use in men diagnosed with prostate cancer.

Prostate cancer and prostatic diseases

Porten SP, Smith A, Odisho AY, Litwin MS, Saigal CS, Carroll PR, Cooperberg MR, Urologic Disease of America Project

Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma.

Cancer

Porten S, Siefker-Radtke AO, Xiao L, Margulis V, Kamat AM, Wood CG, Jonasch E, Dinney CP, Matin SF

Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.

Cancer cell

Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K, Siefker-Radtke A, Czerniak B, Dinney CP, McConkey DJ

Xanthogranulomatous pyelonephritis presenting with a left flank mass.

Case reports in medicine

Zaid UB, Porten SP, Cinman NM, Sanford TH, Breyer BN

Should histologic variants alter definitive treatment of bladder cancer?

Current opinion in urology

Willis DL, Porten SP, Kamat AM

Refining patient selection for neoadjuvant chemotherapy before radical cystectomy.

The Journal of urology

Culp SH, Dickstein RJ, Grossman HB, Pretzsch SM, Porten S, Daneshmand S, Cai J, Groshen S, Siefker-Radtke A, Millikan RE, Czerniak B, Navai N, Wszolek MF, Kamat AM, Dinney CP

Gunshot wounds to the lower urinary tract: a single-institution experience.

The journal of trauma and acute care surgery

Cinman NM, McAninch JW, Porten SP, Myers JB, Blaschko SD, Bagga HS, Breyer BN

The role of active surveillance in the management of prostate cancer.

Journal of the National Comprehensive Cancer Network : JNCCN

Fung-Kee-Fung SD, Porten SP, Meng MV, Kuettel M

Active surveillance: does serial prostate biopsy increase histological inflammation?

Prostate cancer and prostatic diseases

Glass AS, Porten SP, Bonham M, Tran TC, Cowan JE, Punnen S, Chan JM, Carroll PR

High-risk nonmuscle invasive bladder cancer: definition and epidemiology.

Current opinion in urology

Porten SP, Cooperberg MR

Commentary on refractory ischemic priapism.

Translational andrology and urology

Garcia M, Porten S, Lue TF

Changes in cancer volume in serial biopsies of men on active surveillance for early stage prostate cancer.

The Journal of urology

Porten SP, Whitson JM, Cowan JE, Perez N, Shinohara K, Carroll PR

Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Porten SP, Whitson JM, Cowan JE, Cooperberg MR, Shinohara K, Perez N, Greene KL, Meng MV, Carroll PR

Factors associated with downgrading in patients with high grade prostate cancer.

Urologic oncology

Whitson JM, Porten SP, Cowan JE, Simko JP, Cooperberg MR, Carroll PR

The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer.

The Journal of urology

Whitson JM, Porten SP, Hilton JF, Cowan JE, Perez N, Cooperberg MR, Greene KL, Meng MV, Simko JP, Shinohara K, Carroll PR

The example of CaPSURE: lessons learned from a national disease registry.

World journal of urology

Porten SP, Cooperberg MR, Konety BR, Carroll PR

Prostate cancer: reducing overtreatment: active surveillance in low-risk disease.

Nature reviews. Urology

Whitson JM, Porten SP, Carroll PR

Outcomes of active surveillance for men with intermediate-risk prostate cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Cooperberg MR, Cowan JE, Hilton JF, Reese AC, Zaid HB, Porten SP, Shinohara K, Meng MV, Greene KL, Carroll PR

Disproportionate presentation of high risk prostate cancer in a safety net health system.

The Journal of urology

Porten SP, Richardson DA, Odisho AY, McAninch JW, Carroll PR, Cooperberg MR

Hypertension is associated with increased urinary calcium excretion in patients with nephrolithiasis.

The Journal of urology

Eisner BH, Porten SP, Bechis SK, Stoller ML

Prevalence and severity of undiagnosed urinary incontinence in women.

The American journal of medicine

Wallner LP, Porten S, Meenan RT, O'Keefe Rosetti MC, Calhoun EA, Sarma AV, Clemens JQ

Office management of pediatric primary nocturnal enuresis: a comparison of physician advised and parent chosen alternative treatment outcomes.

The Journal of urology

Diaz Saldano D, Chaviano AH, Maizels M, Yerkes EB, Cheng EY, Losavio J, Porten SP, Sullivan C, Zebold KF, Hagerty J, Kaplan WE

Math5 is required for both early retinal neuron differentiation and cell cycle progression.

Developmental biology

Le TT, Wroblewski E, Patel S, Riesenberg AN, Brown NL

Math5 is required for retinal ganglion cell and optic nerve formation.

Development (Cambridge, England)

Brown NL, Patel S, Brzezinski J, Glaser T

Custom People Group: